The search for new drugs can't be left in human hands
In a world supported and sustained by new technology emerging daily, the Benevolent AI boss says the only way to break new ground in medicine is to dig out new drugs through AI.
Jackie Hunter , BenevolentBio
I am CEO of BenevolentBIo (formerly Stratified Medical Ltd) the bioscience arm of BenevolentAI. I am also a Director of BenevolentAI. BenevolentBio applies BenevolentAI’s technology to drug discovery and development and provides the company with the insight it needs to significantly improve the pharmaceutical R&D process. I am also a non-Executive Director of Chiltern International Group, a global CRO.
Currently I am a member of the Governing Board of the University of Hertfordshire and was previously on the Governing Board of Royal Holloway and Bedford College, University of London.
I have run a global R&D organisation and also been CEO of an SME. I have served as charity trustee and a non-exec director of an AIM listed biotechnology company, Proximagen, as well as serving on many national and international boards and research panels.
In 2010 I received a CBE in Queen’s Birthday Honours list for Services to the Pharmaceutical Industry and was awarded the 2010 Women of Achievement in Science, Engineering and Technology (SET) in the category SET Discovery, Innovation and Entrepreneurship. In 2012 I was elected a fellow of the British Pharmacological Society and in 2013 I was honoured to receive a Personal Chair in Life Sciences Innovation from St Georges Hospital Medical School. In 2015 I became a Fellow of the Zoological Society of Lnond and in 2016 I received an Honorary DSc from Brunel University and was elected a Fellow of the Royal Society of Biology,
Specialtiies: Open Innovation in Healthcare and Life Science R&D, collaborative research between academia and industry and large public-private partnerships: pharmaceutical R&D in general with specialist technical knowledge of the Neurosciences therapeutic area; driving cultural change in order to create innovation and value. The role of AI and machine learning in drug discovery and development.